Skip to content

Timing of H. pylori eradication therapy in ESD perioperative period of early gastric cancer

Timing of H. pylori eradication therapy in ESD perioperative period of early gastric cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055169
Enrollment
Unknown
Registered
2022-01-02
Start date
2018-10-01
Completion date
Unknown
Last updated
2023-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early gastric cancers

Interventions

Group A:ESD preoperative eradication
Group B:Post-ESD eradication

Sponsors

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Those who have been diagnosed as early gastric cancer (EGC) and high-grade intraepithelial neoplasia (HGN) by endoscopic diagnosis or/and biopsy and will receive endoscopic treatment (ESD) in our hospital; 2. Patients with definite H. pylori infection, that is, positive for any of the following tests: breath test, rapid urease test, stool antigen, and histopathology showing H. pylori; 3. Those who signed informed consent and were able to accept outpatient follow-up.

Exclusion criteria

Exclusion criteria: 1. Those who have received H. pylori eradication therapy in the past 1 month; 2. Those who have undergone gastric surgery (partial resection) (those who have undergone gastric ESD are not excluded); 3. Those with poor general condition, or those with contraindications to endoscopy; 4. Those who are pregnant and breastfeeding; 5. Those who are allergic to eradication drugs.

Design outcomes

Secondary

MeasureTime frame
Occurrence rate of gastritis-like epithelium;ESD complete removal rate;ESD curative resection rate;ESD unit operating time;Complications and incidence of simultaneous/metachronous cancer;Hp eradication rate;Hp 6 month recurrence rate (reburn);Hp 1-year recurrence rate (reinfection);

Primary

MeasureTime frame
Ratio of negative margins at ESD level;Ratio of negative at 5mm mark;

Countries

China

Contacts

Public ContactWu Xi
wuxi@pumch.cn+86 13683296860

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026